Abstract:
N-Benzoyl arylsulfonamides having the formula (I) are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.
Abstract:
Mutant peptides derived from wild-type human Bcl-2 are disclosed. Assays to identify substances which block the ability of Bcl-2 to inhibit apoptosis also are disclosed.
Abstract:
The present invention relates to peptides derived from the wild-type human Bad peptide which bind to a member of the Bcl-2 family of proteins. The peptides of the present invention can be used in an assay to identify candidate substances which induce or promote apoptosis in cells.
Abstract:
Methods of detecting binding of a putative ligand to a C-enriched target molecule, methods of screening for compounds which bind to a C-enriched target molecule, methods for calculating the dissociation constant of a ligand compound which binds to a C-enriched target molecule, and methods employed in the determination of the specific amino acids in a C-enriched target molecule affected by the binding of a ligand, as well as compounds identified by these screening methods, are provided herewith.
Abstract:
The present invention relates to peptides derived from the wildtype human smac (DIABLO) protein which binds to a member of an IAP family member. The peptides of the present invention can be used in an assay to identify candidate substances which induce or promote apoptosis in cells.
Abstract:
A method of killing cancer cells comprising inhibiting the function of a gene selected from the group consisting of CDK8, STK33, PRKCM, PRKACA, ACVR1B, CDK5R1, CDC42BPB, MPP6, and CDC42BPA; pharmaceutical compositions comprising an inhibitor of the same, and a method of detecting cellular hyperplasia. More specifically, the inhibitors are oligonucleotides and siRNA.
Abstract:
The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional 15N/1H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional 15N/1H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three-dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.
Abstract:
The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional 15N/1H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional 15N/1H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three-dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.
Abstract:
Mutant peptides derived from wild-type human Bcl-2 are disclosed. Assays to identify substances which block the ability of Bcl-2 to inhibit apoptosis also are disclosed.